Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Public health policy

4163 - Worldwide comparison of colorectal cancer survival, by topography and stage at diagnosis (CONCORD-2)


22 Oct 2018


Proffered paper session - Public health policy


Cancer Prevention

Tumour Site

Colon and Rectal Cancer


Sara Benitez Majano


Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297


S. Benitez Majano, V. Di Carlo, M. Nikšić, M.P. Coleman, C. Allemani, . CONCORD Working Group

Author affiliations

  • Department Of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4163


Colorectal cancer is one of the most important causes of cancer morbidity and mortality worldwide. We have explored international variation in colorectal cancer survival, by topography and disease extension.


We analysed data on 4,877,818 individual malignant tumours of the colon or rectum diagnosed during 1995-2009, provided by 228 population-based cancer registries in 55 countries participating in the CONCORD programme for global surveillance of cancer survival. We defined four anatomic sub-sites: right colon, left colon, other/unspecified colon, and rectum. Data on stage at diagnosis were available for 655,844 patients diagnosed during 2001-2009, from 63 cancer registries in 21 countries. We only included registries with stage data available for 70% or more of patients. We estimated age-standardised net survival at five years after diagnosis, by country, topography and stage.


During 2004-2009, 5-year net survival ranged from 29 to 70% for patients with colon cancer, and from 32 to 74% for rectal cancer. In most countries, survival was comparable between tumours in the right colon (40-69%) and the left colon (33-71%), but tended to be lower for tumours of unspecified/other topography (18-63%). Five-year survival for localised colorectal cancer (38-94%) was considerably higher than for advanced disease (22-75%).


Five-year survival from colorectal cancer varies widely between countries, but also by sub-site and stage. These results offer the widest picture on the availability of data on stage at diagnosis and stage-specific cancer survival worldwide. Complete and standardised registration of stage at diagnosis is essential for valid population-based monitoring and international comparisons of cancer survival.

Clinical trial identification

Legal entity responsible for the study

London School of Hygiene and Tropical Medicine.


Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League (Bern, Switzerland), and University of Kentucky (Lexington, KY, USA).

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.